Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Yearbook of Neurology and Neurosurgery

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0513-5117(08)70110-8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

  2005cited by this paper

• Thermodynamics in Gliomas: Interactions between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma

  2017cites this paper
• 3 Key Principles in Glioblastoma Therapy

  2017cites this paper
• El tratamiento médico de la recidiva del glioblastoma: experiencia del hospital de Sant Pau 2005-2014

  2016influential citation
• The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma.

  2016cites this paper
• Emodin Suppresses Maintenance of Stemness by Augmenting Proteosomal Degradation of Epidermal Growth Factor Receptor/Epidermal Growth Factor Receptor Variant III in Glioma Stem Cells

  2015cites this paper
• Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

  2015cites this paper
• Nonsurgical treatment of recurrent glioblastoma.

  2015cites this paper
• Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.

  2014cites this paper
• Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes

  2014cites this paper
• Glial progenitors as targets for transformation in glioma.

  2014cites this paper
• Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.

  2014cites this paper
• Core–Shell Nanoparticle-Based Peptide Therapeutics and Combined Hyperthermia for Enhanced Cancer Cell Apoptosis

  2014cites this paper
• Targeting molecular addictions in cancer

  2014influential citation
• Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates

  2013cites this paper
• Genetic Profiling: Searching for Novel Genetic Aberrations in Glioblastoma

  2013cites this paper
• Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.

  2013cites this paper
• Acridine Yellow G Blocks Glioblastoma Growth via Dual Inhibition of Epidermal Growth Factor Receptor and Protein Kinase C Kinases*

  2012cites this paper
• Key concepts in glioblastoma therapy

  2012cites this paper
• Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.

  2011cites this paper
• Signal transduction inhibitors and antiangiogenic therapies for malignant glioma

  2011cites this paper
• Molecular diagnostics of gliomas.

  2011cites this paper
• Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme

  2011cites this paper
• Mouse models in neurological disorders: applications of non-invasive imaging.

  2010cites this paper
• Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity

  2009cites this paper
• EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines

  2009cites this paper
• The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro

  2009cites this paper
• Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment

  2009cites this paper
• Heterogeneous activation of the TGFβ pathway in glioblastomas identified by gene expression-based classification using TGFβ-responsive genes

  2009cites this paper
• L 3 Differences in the kinase binding modes of imatinib , nilotinib and dasatinib are reflected in Abl transphosphorylation assays

  2009cites this paper
• Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

  2008cites this paper
• The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer

  2008cites this paper
• Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

  2008cites this paper
• Survival from brain tumours in England and Wales up to 2001

  2008cites this paper
• Glioblastoma Multiforme : Multidisciplinary Care and Advances in Therapy

  2008cites this paper
• Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers

  2008cites this paper
• Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study

  2008cites this paper
• Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.

  2008cites this paper
• Diagnostische und therapeutische Strategien bei rezidivierten Gliomen

  2007cites this paper
• CASE OF THE WEEK PROFESSOR YASSER METWALLY

  2007cites this paper
• Multifaceted Dysregulation of the Epidermal Growth Factor Receptor Pathway in Clear Cell Sarcoma of the Kidney

  2007cites this paper
• An update on mouse brain tumor models in cancer drug discovery

  2007cites this paper
• Targeting HER proteins in cancer therapy and the role of the non-target HER3

  2007cites this paper
• Treatment Options for Glioblastoma and other Gliomas

  2006influential citation
• Brain Tumor Stem Cells

  2006cites this paper
• Molecular Targeting and Treatment of EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibody L8A4

  2006cites this paper
• Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: Correlation with androgen independence

  2006cites this paper
• Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.

  2006cites this paper